Ann Clin Microbiol 2020;23:125-134. Performance of Modified-EUCAST Rapid Direct Antimicrobial Susceptibility Testing on Clinical Urine Samples
| Species | Antimicrobial agent | Modified-EUCAST rapid direct AST | Conventional AST | MIC by E-test (μg/ml) | Interpretation |
|---|---|---|---|---|---|
| Escherichia coli | Aztreonam | R | S | 0.5 | ME |
| Escherichia coli | Cefepime | R | S | 4 | MnE |
| Escherichia coli | Cefepime | R | S | 8 | MnE |
| Escherichia coli | Amikacin | R | S | 4 | ME |
| Escherichia coli | Cotrimoxazole | S | R | 1.5 | Agreement |
| Gentamicin | R | S | 32 | Agreement | |
| Aztreonam | R | S | 48 | Agreement | |
| Escherichia coli | Cotrimoxazole | R | S | ≥32 | Agreement |
| Escherichia coli | Cotrimoxazole | R | S | 48 | Agreement |
| Klebsiella pneumoniae | Tigecycline** | S | R | 2 | Agreement |
| Morganella morganii | Tigecycline | S | R | 1.5 | Agreement |
| Proteus vulgaris* | Tigecycline | S | R | 16 | VME |
| Proteus vulgaris* | Tigecycline | S | R | 2 | Agreement |
| Proteus mirabilis* | Tigecycline | S | R | 24 | VME |
| Imipenem | S | R | 1 | Agreement |
*The most very major errors were noted in tigecycline for P. vulgaris and P. mirabilis. **The FDA MIC breakpoints for susceptible (≤ 2 μg/ml), intermediate (4 μg/ml), and resistant (≥ 8 μg/ml) were used to categorize tigecycline susceptibility in Enterobacteriaceae strains.
Abbreviation: EUCAST, European committee on antimicrobial susceptibility testing; AST, antimicrobial susceptibility test; MIC, minimal inhibitory concentration; R, resistant; S, susceptible; ME, major error; MnE, minor error; VME, very major error.